RSS

Tremfya

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more

News

The National Institute for Health and Care Excellence (NICE) has published its positive guidance for the first selective interleukin (IL)-23 inhibitor to treat moderate to severe plaque psoriasis. more

News

The National Institute for Health and Care Excellence (NICE) has issued its final appraisal determination (FAD) to Janssen recommending Tremfya (guselkumab) for treatment of adults with moderate to severe plaque psoriasis. more

News

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more

News

New data, presented at the 2018 American Academy of Dermatology (AAD) Annual Meeting, has demonstrated that Tremfya (guselkumab) provides long-term skin clearance in patients with moderate to severe plaque psoriasis. more

News

Janssen has announced that its treatment for moderate-to-severe plaque psoriasis is now available in the UK for adult patients who are candidates for systemic therapy. more

News